Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
Phase of Trial: Phase III
Latest Information Update: 29 Jun 2018
At a glance
- Drugs Macitentan (Primary)
- Indications Eisenmenger complex
- Focus Adverse reactions
- Acronyms MAESTRO-OL
- Sponsors Actelion Pharmaceuticals
- 15 Jan 2018 Status changed from active, no longer recruiting to completed.
- 11 Jan 2018 Planned End Date changed from 30 Nov 2017 to 15 Jan 2018.
- 11 Jan 2018 Planned primary completion date changed from 30 Nov 2017 to 15 Jan 2018.